Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model
Gabriel Sosne,1 George W Ousler2 1Kresge Eye Institute, Wayne State University, Detroit, MI, 2Ora Inc, Andover, MA, USA Background: The purpose of this study was to evaluate the safety and efficacy of thymosin beta 4 ophthalmic solution (RGN-259; Tβ4) in subjects with moderate to severe d...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2015-05-01
|
| Series: | Clinical Ophthalmology |
| Online Access: | http://www.dovepress.com/thymosin-beta-4-ophthalmic-solution-for-dry-eye-a-randomized-placebo-c-peer-reviewed-article-OPTH |